Disrupting Spinal Caveolin-1 Scaffolding Prevents as well as Reverses Tolerance to Opioid Antiallodynia in Treating Neuropathic Pain in Rats

Nai-Jiang Liu* and Haixia Li
Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, Brooklyn, New York, USA

Abstract
Pharmacodynamic opioid analgesic tolerance, resulting in escalating doses of opioids, and paradoxical opioid-induced nociception, remains a major impediment to prescribing opioids for chronic pain management, often leading to undermanaging pain and deleterious consequences thereof. To date, none of the many downstream cellular adaptations proposed to be causally associated with opioid tolerance have reached clinical relevance and identification of underlying upstream mechanisms common to most, if not all tolerance adaptations, has remained elusive. We predicted that altered functionality of the predominant scaffolding protein Caveolin 1 (Cav1) is an upstream mechanism fundamental to the developmental and maintenance of morphine anti-allodynic tolerance based on our earlier finding that opioid receptors are present in a macromolecular signaling complex whose formation likely requires a scaffolding protein(s) as well as the ability of chronic opioids to orchestrate functionally interconnected alterations among signaling molecules. Findings obtained in rats utilizing the spinal nerve ligation neuropathic pain model demonstrated that (1) persistent interference with spinal Cav1 scaffolding and/or spinal Src kinase activity (which is activated by opioids and modulates Cav1 functionality via its phosphorylation) abolished the development of spinal morphine anti-allodynic tolerance and (2) acute disruption of spinal Cav1 scaffolding and/or spinal Src activity after tolerance was fully manifest reinstated opioid naïve anti-allodynic effects of intrathecal morphine. These findings indicate the relevance to pain management of developing anti-opioid tolerance pharmacotherapies that disrupt Cav1 scaffolding in the presence of chronic opioids. The clinical success of such opioid adjuvants is foreshadowed by the potential to concomitantly interrupt multiple analgesic/anti-allodynic tolerance mechanisms.

Keywords: Anti-allodynia; Caveolin 1; Chronic pain; Opioid tolerance

Introduction
Opioids continue to be amongst the most efficacious drugs for pain management, being essentially indispensable for mitigating pain that is unresponsive to non-pharmacological treatments and non-opioid analgesics [1]. However, despite their clinical usefulness, pharmacodynamic opioid analgesic tolerance, i.e., classical pharmacological opioid analgesic tolerance, which is independent of disease progression [2-7], is a major contributor to the need for escalating opioid doses during chronic pain management and thus to the current epidemic of death by opioid overdose. This substantially compromises the clinical utilization of opioids, leading to undermanaging nociception, which itself can have substantial damaging consequences [8-13], a poignant example of which is that minimizing nociception following surgery is a critical determinant of speed of recovery [14].

µ-Opioid receptor (MOR) downregulation and G protein uncoupling [15-18] have been thought to be foundational to opioid analgesic tolerance. However, many observations challenge this perspective, e.g., (a) substantial opioid analgesic tolerance develops without accompanying MOR downregulation [19-22], MOR G protein uncoupling [23], arrestin binding and/or endocytosis [24,25]; (b) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (c) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (d) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (e) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (f) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (g) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (h) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (i) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (j) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (k) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (l) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (m) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (n) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (o) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (p) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (q) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (r) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (s) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (t) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (u) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (v) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (w) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (x) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (y) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25]; (z) development of opioid analgesic tolerance is often accompanied by upregulation of MOR density [26-31], increased efficacy of MOR agonists [27,28], arrestin binding and/or endocytosis [24,25];

Strikingly, chronic morphine induces coordinated, interrelated changes in signaling molecules downstream from MOR. These include: (a) adaptations that collectively shift MOR signaling from AC inhibitory to stimulatory [33-35,38,40,42]; (b) increased expression/translocation of a panoply of signaling molecules, e.g., Protein Kinase C (PKC) [47-49], Mitogen Activated Protein Kinase (MAPK) [50-52], Ca2+/calmodulin-dependent protein Kinase IIa (CamKIIa) [53], mGluR [54], as well as reciprocal modulation of two phospholipase C isoforms (b1 and b3) [37]. The manifestation of synchronized, functionally interconnected alterations in signaling molecules in response to chronic morphine, along with our recent finding that MOR and the kappa-opioid receptor exist, at least in part, within a common macromolecular signaling complex [55,56] suggests that scaffolding proteins likely play a pivotal role in acute as well as chronic opioid sequelae.

One such scaffolding protein is Caveolin 1 (Cav1), the principal structural protein of caveolae, membrane microdomains [57,58] containing a wide spectrum of signaling proteins [e.g., AC, MAPK, Src, functional G protein-coupled receptors [57,59,60]. This enables Cav1 to spatially and temporally organize signaling complexes, thereby
modulating their interactions [61-64]. Importantly, Cav1 can form scaffolds outside of as well as within caveolae [65,66], which also regulate interactions among plasma membrane signaling proteins. This is notable since CNS neurons do not contain structurally defined caveolae [67], but do contain Cav1 [66-72].

Cav1 influences on signaling vary, depending on linked signaling partners, cellular context and the nature of specific signaling pathways. For example, Cav1 suppresses Extracellular signal-Regulated Kinase (ERK)-induced activation of the Grb2-Sos-Ras pathway [73], but facilitates ERK activation of the PI3 kinase pathway and insulin receptor signaling [74,75]. Cav1 scaffolding functionality is also dependent on its phosphorylation. The nonreceptor tyrosine kinase Src, whose activity is augmented by MOR agonists [76], phosphorylates Cav1 at tyrosine 14 (pY14Cav1) [77-79], increasing Cav1 recruitment of signaling molecules [79-83]. This pliability of Cav1 scaffolding and its modulation by Src phosphorylation makes both ideally suited to play a pivotal role in differentially altering interactions among signaling molecules, facilitating their assembly into signaling complexes, altering the relative predominance of signaling pathways, as we and others have demonstrated occurs in response to chronic opioids [35,39,44,46,84-86]. Chronic morphine augments Cav1 scaffolding [87] and expression in spinal cord [86] underscores its likely relevance to opioid anti-allodynic tolerance mechanisms.

Accordingly, this study tests the hypothesis that the scaffolding functionality of Cav1 is critical to both the development and maintenance of opioid anti-allodynic tolerance. Findings obtained utilizing the spinal nerve ligation chronic pain model (SpNL) demonstrated that chronic interference with spinal Cav1 scaffolding and/or chronic pharmacological inhibition of spinal Src activity prevented the onset of spinal morphine anti-allodynic tolerance. Strikingly, acute blockade of spinal Cav1 scaffolding and/or acute pharmacological inhibition of spinal Src activity fully reversed tolerance to the anti-allodynic effects of morphine after tolerance had been fully developed. These findings imply the clinical utility of developing opioid adjuvants that target spinal Cav1 and/or spinal Src to minimize tolerance to opioids in pain mitigation. This would attenuate the need for opioid dose escalation, facilitating the use of opioids in pain management.

Methods

Animals and Housing

Experiments utilized male Sprague-Dawley rats (Charles River Laboratories, Kingston, NY; 250-300 g) that were maintained in a controlled environment on a 12-hour light/dark cycle. Food and water were available ad libitum. Our Institutional Animal Care and Use Committee reviewed and approved all experimental procedures, which conformed to applicable national/international guidelines. Animals were randomly assigned to experimental and control groups. Each animal was used only once. Power analysis guided experimental group size, which is indicated in relevant sections of Results.

Spinal Nerve Ligation (SpNL)

As we and others have reported [88-94], an incision was made above the lumbar spine. The left transverse process of vertebra L6 was exposed under isoflurane anesthesia (2.5%). The left L5 spinal nerve was tightly ligated with silk thread No. 6 and cut distal to the ligation. Peripheral neuropathic pain arises within 24 h in the ipsilateral hind paws, persisting for months [88,89,93,94], which is displayed as mechanical allodynia. General behavior of the rats was monitored before and after the surgery. Rats showing difficulty elevating the hind paw ipsilateral to SpNL were excluded from the study.

Implantation of intrathecal cannulas

A permanent indwelling cannula was inserted into the lumbar spinal cord subarachnoid space as we have described and utilized previously for spinal drug delivery [55,56,94]. Spinal cannula was implanted concomitant with SpNL. Briefly, animals were anesthetized as described above, and an 8.0 cm PE-10 catheter (Becton Dickinson and Company, Franklin Lanes, and NJ) was inserted into the spinal subarachnoid space via the atlanto-occipital membrane. The cephalic portion of the catheter was externalized through the skin on the dorsal side of the neck, where it was secured in place, being relatively inaccessible to the paws. All animals utilized in studies appeared to be free of infection upon gross inspection and did not exhibit any motoric impairment, assessed using the righting reflex and the inclined plane test.

Intrathecal administration of drugs

Drugs were applied to the spinal cord subarachnoid space over a 60-second period via the indwelling i.t. cannula seven days following cannula implantation. Flushing the cannula with an additional 10 μl of saline ensured complete delivery. I.t. pretreatment with either caveolin domain competing peptide (CSD), scrambled caveolin domain competing peptide (S-CSD), PP2, PP3 or CSD+PP2 was applied 45 min before i.t. application of morphine. I.t. morphine dose responsiveness was determined 30 min after each i.t. application of morphine, immediately before the application of the following dose of morphine [95-97]. Dose responsiveness was always performed in the identical ascending pattern among the various experimental groups, minimizing any potential confounds resulting from differences in duration of action among the various ascending doses of i.t. morphine.

Chronic morphine administration generating spinal or systemic morphine tolerance

Spinal morphine tolerance was achieved via i.t. application of 15 μg morphine daily for at least six days [98,99]. Systemic morphine tolerance was accomplished by implanting morphine pellet subcutaneously under isoflurane anesthesia (2.5%), one pellet on day 1, two pellets on day 3 and three pellets on day 5 (each containing 75 mg morphine base) [87,100].

Quantification of alldynia and acute thermal nociception

Mechanical allodynia was quantified by measuring withdrawal thresholds of the hind paw ipsilateral to the SpNL in response to the application of von Frey force as we described previously [101]. Briefly, rats were placed on a wire mesh surface, covered by an inverted plastic cage and allowed to habituate for 15 min. A hand-held probe containing a rigid filament was applied to the plantar surface of the hind paw with increasing force. The applied pressure (g) that elicited paw withdrawal was automatically recorded using Electronic von Frey Anesthesiometer (IITC Life Science, Woodland Hills, CA). A cutoff force of 60 g was employed to prevent tissue damage. Tail flick latency in response to the application of radiant heat applied to the tail using an Algesia Meter (IITC, Woodland Hills, CA) was used to assess acute nociception and its modulation by i.t. morphine as we described previously [102]. Intensity of the radiant heat was adjusted such that baseline values were in the range of 3.0-4.5 sec. Tissue damage was prevented by imposing a 10 sec cutoff. All testing was performed blind to treatment.
Drugs

CSD (H-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Asp-Gly-Ile-Trp-Lys-Ala-Ser-Phe-Thr-Thr-Phe-Thr-Val-Thr-Lys-Tyr-Trp-Phe-Tyr-Arg-OH) and S-CSD (H-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Met-Lys-Trp-Lys-Tyr-Gly-Ile-Asp-Lys-Ala-Ser-Phe-Thr-Thr-Phe-Thr-Val-Thr-Lys-Tyr-Trp-Phe-Tyr-Arg-OH) were obtained from Millipore Corporation (Bedford, MA). 3-(4-chlorophenyl) 1 (1,1-dimethyllethyl)-(1H)-pyrazolo [3,4-d]pyrimidin-4-amine (PP2, a Src kinase inhibitor) and 1-Phenyl-1H-pyrazolo [3,4-d]pyrimidin-4-amine (PP3, a negative control for PP2) was obtained from Tocris (Ellisville, MO). Morphine sulfate and 75 mg morphine base pellets were obtained from NIDA. CSD (up to 10 µg), S-CSD (10 µg), PP2 (300 ng) and PP3 (300 ng) were solubilized in Dimethyl Sulfoxide (DMSO, up to 5 µl) while morphine sulfate (up to 20 µg) was prepared in 5 µl saline.

Data analysis

Only-way ANOVA was used to compare treatment effect within group and two-way repeated measure ANOVA was used to compare treatment by time/dose effects among groups. Bonferroni post hoc test identified specific groups between which significant effects were observed. P < 0.05 was considered significant. Statistical comparisons were made using Prism 6 software. Data are expressed as the mean +/- Standard Error of the Mean (SEM).

Results

Combined Intrathecal (i.t.) treatment with CSD and PP2 prevents development of spinal opioid anti-allodynic tolerance induced by chronic i.t. morphine. In these experiments, spinal opioid analgesic tolerance was achieved by the i.t. application of 15 µg morphine, once daily for six days. Figure 1A illustrates that this spinal treatment produced substantial tolerance, essentially eliminating anti-allodynic responsiveness to i.t. morphine (15 µg), assessed using the electronic von Frey test. By day 3, roughly half the initial anti-allodynic effect of i.t. morphine was no longer manifest and by day 6, essentially the totality of i.t. morphine responsiveness had been eliminated. In striking contrast, there was no loss of morphine’s effectiveness in chronic morphine-treated animals that had been pretreated intrathecally with CSD+PP2 (10 µg and 300 ng, respectively), 45 min prior to i.t. morphine. Two-way ANOVA revealed a significant treatment effect (i.t. CSD+PP2 vs. vehicle; n=10 and 6, respectively) (F1,18=3.4, p<0.001) after day 2 of i.t. morphine (p<0.0001 for days 3-6).

Figure 1B illustrates that the totality of the rightward shift of i.t. morphine dose-responsiveness (2.5-20 µg) was eliminated by pretreatment with CSD+PP2, revealing that their tolerance abating effect was not limited by the dose of i.t. morphine. Two-way ANOVA showed a significant treatment effect among the 3 groups: F2,15=54.11, p<0.0001). Significant differences were observed between Chronic Morphine (CM) group (n=5) and CSD+PP2+CM group (n=6) as well as between CM group and morphine naïve group (n=7) (p<0.0001 for both comparisons), but not between CSD+PP2+CM and opioid naïve animals (p>0.05). The latter comparison indicates that pretreatment with i.t. CSD+PP2 abolished development spinal morphine anti-allodynic tolerance. This effect of i.t. CSD+PP2 results specifically from its anti-tolerance action since (a) i.t. treatment with vehicle (DMSO) had no effect on tolerance development and (b) as shown in Figure 1C, chronic i.t. treatment with CSD+PP2 did not alter the anti-allodynic effect of acute i.t. morphine in the absence of chronic spinal morphine treatment (F1,18=3.4, p<0.05, n=4 for each point), i.e., i.t. CSD+PP2 neither directly influenced basal von Frey thresholds nor spinal morphine anti-allodynic responsiveness. Instead i.t. CSD+PP2 specifically interrupted mechanisms underlying opioid tolerance development, enabling i.t. morphine to produce normative anti-allodynia despite the chronic morphine treatment (Figure 1).

I.t. treatment with CSD+PP2 reverses spinal opioid anti-allodynic tolerance. Prevention of the development of spinal opioid anti-allodynic tolerance by i.t. CSD+PP2 does not necessarily indicate the ability of this treatment to reverse tolerance, once it has fully developed. In order to determine if i.t. CSD+PP2 was also able to acutely reverse opioid anti-allodynic tolerance, we determined the effect of intrathecally applying CSD+PP2 on i.t. morphine anti-allodynia subsequent to tolerance development (Figure 2A). One-way ANOVA revealed a significant treatment effect among days 1, 9, and 11 (F2,21=58.4, p<0.0001), significant differences being observed between effects on day 1 vs. day 9 (when anti-allodynic tolerance was fully manifest) (P<0.0001) and effects on day 9 vs. day 11 (when i.t. CSD+PP2 resulted in the biggest reversal) (p<0.01), but not between days 1 and 11 (p>0.05). The latter comparison revealed that tolerance reversal was complete. As illustrated in Figure 2A (n=8), following 9-days of spinal morphine treatment, morphine tolerance was fully manifest, essentially eliminating the totality of morphine’s anti-allodynic effect. The i.t. application of CSD+PP2 on day 10 (45 min prior to intrathecally administering morphine) restored >95% of the initial i.t. morphine-induced anti-allodynia.

We also investigated the effect of i.t. CSD+PP2 on tail flick latency (Figure 2B) in order to investigate whether or not the acute anti-tolerance effect of i.t. CSD+PP2 was pain modality specific. As was observed for neuropathic pain, one-way ANOVA revealed a significant treatment effect (F2,11=17.5, p<0.0001; n=5) among days 1, 9, and 11, significant differences being observed on day 1 vs.
day 9 (when tolerance was fully manifest) (P<0.01) and on day 9 vs. 11 (when CSD+PP2 showed the biggest reversal) (p<0.01). No treatment effect was observed between day 1 and day 11 (p>0.05), indicating that tolerance reversal was essentially complete, i.e., CSD+PP2 restoring >90% of the analgesic effect of i.t. morphine manifest prior to chronic spine morphine (Figure 2).

Figure 2: i.t. treatment with CSD and PP2 reverses i.t. morphine tolerance. A: The von Frey allogrynia test showed that i.t. morphine had lost most of its anti-allodynic effectiveness after 9 days of daily i.t. morphine treatment (15 µg). B: CSD+PP2 (10 µg and 300 ng, respectively) applied on day 10, 45 min before i.t. morphine, fully restored spinal anti-allodynic morphine responsiveness, which lasted for 2 days (n=8).

Figure 3: i.t. treatment with either CSD or PP2 reverses i.t. morphine tolerance. Spinal anti-allodynic tolerance to i.t. morphine was generated as described in the legend to figure 1. The von Frey allodynia test revealed that i.t. morphine had lost most of its anti-allodynic effect 7-8 days following daily i.t. 15 µg morphine. CSD (10 µg) or PP2 (300 ng) fully restored spinal anti-allodynic tolerance. As is illustrated in Panel A, i.t. morphine lost most of its analgesic effect 9 days following daily 15 µg i.t. morphine treatment. I.t. CSD+PP2, applied on day 10, 45 min before i.t. morphine, fully restored morphine antinociception, which lasted for 4 days (n=5). CSD (Caveolin-1 Scaffolding Domain peptide); PP2 (selective Src inhibitor).

I.t. CSD and PP2, each administered individually, blocked the development as well as maintenance of spinal opioid anti-allodynic tolerance induced by chronic i.t. morphine. We hypothesized that CSD and PP2 would interfere with tolerance by acting at two sequentially interconnected components of tolerance mechanisms, CSD interfering with scaffold by competing with the scaffolding domain within Cav1 while PP2 inhibits Src kinase, known to phosphorylate Tyr 114 of Cav1, thereby modulating its scaffolding ability. Accordingly, we tested the hypothesis that the individual i.t. application of either CSD (10 µg; Figure 3A) or PP2 (300 ng; Figure 3B) would be sufficient to interrupt opioid anti-allodynic tolerance. For the CSD treated group (n=6), one-way ANOVA showed a significant treatment effect (F2,15=14.5, p<0.001) between day 1 and day 7 (when tolerance was fully manifest) (P<0.001) as well as between day 7 and day 8 (when CSD showed the biggest reversal) (p<0.01), but not between day 1 and day 8 (p>0.05). The latter comparison reveals that tolerance reversal was complete.

The PP2 treated group followed suit. One-way ANOVA showed a significant treatment effect (F2,12=14.3, p<0.001) between day 1 and day 8 (when tolerance was fully manifest) (P<0.001) as well as between day 8 and day 9 (when PP2 produced the biggest reversal) (p<0.05) (n=5). As is shown in figure 3, by day 7 of spinal morphine treatment, tolerance had developed to i.t. morphine, essentially eliminating the totality of its anti-allodynic effects. On day 9, i.t. PP2 (Figure 3B), applied intrathecally 45 min prior to the i.t. morphine, attenuated spinal opioid anti-allodynic tolerance, substantially restoring the ability of i.t. morphine to elevate allodynic (von Frey) thresholds.

I.t. CSD blocks both the development and maintenance of spinal opioid tolerance induced by chronic systemic morphine. Recognizing that opioids are frequently given systemically, in addition to intrathecally, we investigated the ability of i.t. CSD to prevent and/or reverse spinal opioid anti-allodynic tolerance induced by systemic chronic morphine, administered via the s.c. implantation of morphine base pellets. These data are shown in Figure 4. Four-way ANOVA included 3 groups: animals receiving s.c. morphine pellets (n=6), morphine-pelleted animals receiving i.t. CSD pretreatment, administered 45 min before morphine pellet implantation on days 1, 3 and 5 (n=7) and morphine-pelleted animals receiving i.t. pretreatment with scrambled CSD (S-CSD; administered as described for i.t. CSD) (n=7). Two-way ANOVA showed a significant treatment effect among the 3 groups (F2,51=153.4, p<0.0001), significant differences being observed between the CSD and S-CSD pretreated groups (p<0.001) as well as between chronic morphine pelleted rats with vs. without i.t. CSD pretreatment p (p<0.0001). Two-days after s.c. implantation of morphine base pellets in the absence of i.t. CSD, the anti-allodynic effect of the systemic morphine was substantially reduced relative to day 1, when cutoff von Frey thresholds were manifest (data not shown). In fact, von Frey thresholds continued to decline through day 8. Notably, in the presence of i.t. CSD (10 µg), the anti-allodynia produced by the implanted morphine pellets was fully manifest, as reflected by the von Frey thresholds reaching cutoff. Blockade of opioid anti-allodynic tolerance development persisted through day 8, 3 days after the last i.t. application of CSD. On day 9 (4 days after the last i.t. application of CSD), when spinal morphine concentrations presumably started to decline, the manifestation of opioid anti-allodynic tolerance began to re-emerge, indicating that blockade of tolerance development by CSD was not an artifact of the random occurrence of tolerance resistance in this particular group of rats. In contrast to CSD, i.t. pretreatment with S-CSD (10 µg applied 45 min before i.t. morphine) failed to alter morphine tolerance development, i.e., there was no difference in tolerance development to chronic systemic morphine between animals that received i.t. S-CSD vs. no spinal treatment.

Spinal treatment with CSD was also effective in reversing systemic morphine-induced spinal opioid tolerance, once it had been fully developed (Figure 4B). One-way ANOVA showed a significant treatment effect (F2,24=6.03, p<0.01, n=8) between day 1 and day 7.
I.t. CSD+PP2 restores i.t. morphine dose responsiveness in animals treated chronically with systemic morphine. In order to assess the full extent of the ability of i.t. CSD+PP2 to reverse tolerance to spinal morphine’s anti-allodynic actions in animals receiving chronic systemic morphine, we investigated the ability of i.t. CSD+PP2 to restore spinal morphine anti-allodynic responsiveness (Figure 5). Groups consisted of opioid naïve animals (‘before pelleting’), opioid tolerant animals (‘after pelleting’) and morphine pelleted animals that also received a one-time i.t. application of CSD+PP2 (‘pelleting, CSD+PP2’), n=8 for each group. Two-way ANOVA revealed significant treatment effects among the groups (F2,18=194.0, p<0.0001). As expected, i.t. morphine dose responsiveness obtained in opioid naïve animals was significantly different from that obtained in morphine pelleted animals (p<0.01). Strikingly, i.t. morphine anti-allodynic dose responsiveness obtained in morphine pelleted (opioid tolerant) animals also significantly differed from that obtained in morphine pelleted animals that had received a one-time i.t. application of CSD+PP2, 45 min prior to quantifying i.t. morphine dose responsiveness (p<0.001). Moreover, morphine dose responsiveness obtained in the latter group did not significantly differ from that obtained in opioid naïve animals (p>0.05), indicating that i.t. CSD+PP2 restored normative spinal morphine anti-allodynia. These data are shown in figure 5, which illustrates that chronic systemic morphine shifted i.t. morphine ED50 from 5.5 µg to 19.7 µg. The totality of this rightward shift in morphine dose responsiveness (anti-allodynic tolerance) was obliterated following the i.t. 45 min pretreatment with CSD+PP2 (10 µg and 300 ng, respectively), i.e., i.t. CSD+PP2 pretreatment of morphine tolerant animals reinstated spinal morphine anti-allodynic responsiveness (ED50=6.4 µg), which was indistinguishable from that observed in opioid naïve rats (5.5 µg).

Figure 4: I.t. CSD, alone, prevents as well as reverses spinal morphine anti-allodynic tolerance induced by systemic morphine. Panel A: von Frey thresholds of the rear paw ipsilateral to Spinal Nerve Ligation (SpNL) were quantified immediately prior to every morphine pellet implantation (performed on day 1, 3 and 5) and/or other daily i.t. treatments. CSD or S-CSD was intrathecally applied 45 min before s.c. morphine pellet implantation. Day 1 represents opioid naïve von Frey thresholds. Throughout the ensuing week, the anti-allodynic effects of the onboard s.c. morphine pellets were robustly manifest in morphine-pelleted rats that had received i.t. CSD. This was reflected by the increase to cutoff in von Frey basal thresholds, which persisted for 3 days following the last i.t. CSD treatment. In contrast, the anti-allodynia resulting from the s.c. morphine pellets remained minimal in rats that had received i.t. S-CSD (open circle) or no i.t. treatment (open square).

Figure 5: I.t. CSD and PP2 reverse spinal tolerance to systemic morphine. Dose-responsiveness to i.t. morphine in opioid naïve rats (open circle; n=8), rats receiving chronic systemic morphine via s.c. implanted morphine pellets (filled circle; n=8) and rats receiving chronic systemic morphine along with a one-time i.t. application of CSD+PP2 (10 µg and 300 ng, respectively; administered 45 min prior to assessing i.t. morphine dose-responsiveness) (filled square; n=8). As expected, the i.t. morphine ED50 was 3.6-fold greater in chronic systemic morphine-treated (tolerant) rats than opioid naïve rats (19.7 µg vs. 5.5 µg), reflecting anti-allodynic tolerance development. In contrast, the i.t. morphine ED50 observed in chronic morphine-treated rats that received i.t. CSD+PP2 prior to dose-response quantification was essentially the same as that of opioid naïve rats (6.4 µg vs. 5.5 µg), underscoring the ability of i.t. CSD+PP2 to acutely eliminate morphine tolerance, even after its full development. CSD (Caveolin-1 Scaffolding Domain peptide); PP2 (selective Src inhibitor).
The hypothesized relevance of protein scaffolding to the development of opioid tolerance was predicated on multiple factors. These include (a) the presence of MOR (and the kappa-opioid receptor) within multimeric signaling complexes [56,103], which invariably require a structural backbone for their formation; (b) the ability of chronic morphine to induce coordinated, interrelated changes in a wide spectrum of signaling molecules downstream from MOR, which is likely to be facilitated by protein scaffolding; as would be (c) the increased emergence and prominence of new signaling strategies in response to chronic morphine, well documented to occur in response to chronic morphine [35,44].

As hypothesized, the combined i.t. application of CSD (which binds to the scaffolding domain of Cav1, thereby effectively blocking scaffolding) and PP2 (which inhibits Src phosphorylation of Cav1) eliminated the development of spinal tolerance to the anti-allodynic effect of intrathecally-applied morphine. Importantly, i.t. CSD+PP2 abolished tolerance development irrespective of the route of chronic morphine administration, abolishing tolerance induced by chronic morphine applied spinally (via daily i.t. application) as well as systemically (via s.c. implantation of morphine base pellets). Since in our formulation, Src is posited to act upstream of Cav1, modifying its scaffolding functionality via phosphorylation, we anticipated that the individual i.t. application of CSD (i.e., interrupting Cav1 scaffolding) or PP2 (inhibiting Cav1 phosphorylation) would mitigate tolerance development to the same extent as would applying CSD together with PP2. As expected, i.t. CSD, in the absence of PP2, or PP2 (in the absence of CSD) retained their ability to eliminate spinal morphine anti-allodynic tolerance. This underscores the putative clinical utility of interfering with Cav1 scaffolding as an adjunctive pharmacotherapy accompanying the use of opioids for pain management.

Many of the proposed biochemical underpinnings of opioid tolerance are not consonant with acute reversal of tolerance once it has fully developed. For example, the long-held view that MOR internalization/downregulation and adenyl cyclase super activation are foundational to opioid analgesic tolerance [104-106] would not be expected to be readily reversed within min following pharmacological intervention, thereby restoring naïve levels of anti-allodynic responsiveness to i.t. morphine. Strikingly, this is exactly what was observed following i.t. CSD+PP2 or their individual i.t. application. In fact, i.t. CSD (0.33 µg) unmasked robust morphine anti-allodynia (from on boarded morphine pellets) in systemic morphine tolerant animals, even in the absence of virtually any pretreatment with CSD. Of note, the acute reversal of morphine anti-allodynic tolerance by CSD (but not S-CSD) and/or PP2 (but not PP3) was not permanent. Within 24-72 hrs, tolerance was once again observed. This reinstatement of tolerance presumably resulted from the run-down of CSD or PP2 concentrations, resulting in the reinstatement of Cav1 scaffolding functionality, characteristic of the opioid tolerant condition. The acute reversal and reestablishment of morphine anti-allodynic tolerance reveals a fluid, temporally dynamic dimension of opioid tolerance, not explicitly provided for in current models of tolerance. Indeed, it is becoming increasingly appreciated that protein function is critically dependent on the milieu of other proteins and other molecules that interact with each other to control a signaling process. The dynamics of these protein communities was originally shown to regulate metabolic processes [107-110], which itself can influence cellular signal transduction at multiple points, e.g., membrane localization of growth factor receptors [111], allowing for adaptation and rapid changes based on cellular and environmental stimuli. The role of metabolomic supramolecular complexes, transient assemblies of proteins that form to regulate seminal processes and the temporal, spatial and conditional dimensions thereof, in modulating neuronal functional states remains unknown. One can envision that just like metabolomes are highly dynamic assemblies of proteins, the effects of their disassembly on the neuronal tolerant state can be equally temporally dynamic. The magnitude of acute reversal by i.t. CSD and/or PP2 of spinal morphine anti-allodynic tolerance as reflected by unmasking the anti-allodynic effects of on boarded morphine pellets were quite variable. This contrasts with the magnitude of the acute reversal by i.t. CSD and/or PP2 of tolerance to the anti-allodynic effects of
intrathecally-applied morphine, which is consistently robust. This dichotomy likely results from the spatially restricted loci of action of intrathecally applied CSD and/or PP2 since such localization would more consistently impact tolerance to the anti-allodynia mediated by spinal opioid receptors (vis a vis i.t. morphine) than the anti-allodynia mediated by opioid receptors located supraspinally as well as spinally, as occurs with systemic morphine. The ability of CSD and/or PP2 to prevent and/or reverse supraspinal morphine anti-allodynic tolerance when they are applied to supraspinal sites remains to be determined.

The variable ability of i.t. CSD/PP2 to unmask the anti-allodynic effects of subcutaneously implanted morphine pellets also contrasts with our observation that the identical i.t. treatment prior to implanting morphine base pellets invariably and robustly maintained the anti-allodynic effects of implanted morphine pellets (i.e., prevented tolerance development) such that the von Frey cutoff threshold was routinely maintained. This dichotomy can result from the bidirectional communication between the spinal cord and brain, e.g., altered spinal cord excitability alters ascending messages, which in turn influences descending modulation arising from the midbrain (e.g., periaqueductal gray) and brainstem (e.g., rostroventromedial medulla) [112,113]. A major difference between preventing vs. acutely reversing spinal opioid tolerance that results from chronic systemic morphine is that spinal tolerance prevention would obviate any influence of spinal opioid tolerance on ascending spinal brain communication (e.g. attenuating endogenous opioid modulation of ascending spinal nociceptive pathways) and resulting supraspinal adaptations, whereas acutely reversing spinal tolerance subsequent to its development would not. Moreover, the temporal profile for the offset of these adaptations might not coincide with that of the acute reversal of spinal opioid tolerance (and presumably the reinstatement of the unfettered activity of spinal ascending pathways). These considerations imply that while prevention and reversal of morphine anti-allodynic tolerance by i.t. CSD/PP2 result from interrupting a common mechanism (Cav1 scaffolding), they likely do not share identical biochemical sequelae.

Multiple clinical reports indicate that persistent opioid exposure can, paradoxically, result in allodynia and hyperalgesia, which often differs from the original pain that is being treated [114-117]. Analogous observations have also been reported in laboratory animals [118]. Interestingly, supraspinal adaptations to chronic systemic morphine (e.g., in the Rostral Ventromedial Medulla (RVM) and dorsolateral funiculus) has been shown to mediate chronic opioid-induced nociception (i.e., hyperalgesia, allodynia) as well as spinal morphine antinoceceptive tolerance [119]. In fact, the former has been causally associated with the latter [119]. This is noteworthy since i.t. CSD and/or PP2 similarly prevented/reversed spinal morphine anti-allodynic tolerance produced by chronic morphine delivered either intrathecally or systemically, indicating that CSD and or PP2 interfere with a fundamental, shared component of multiple tolerance-producing adaptations. Additionally, these considerations suggest that CSD and/or PP2 could be effective in blocking/reversing chronic opioid-induced allodynia/hyperalgesia, further extending the clinical utility of opioids in chronic pain management.

Whereas CSD is specific for interrupting Cav1 scaffolding, Src has many substrates that could influence the development and maintenance of opioid tolerance. For example, chronic morphine-induced activation of Src can not only result in increased tyrosine phosphorylation of Cav1, altering its scaffolding properties, but also the tyrosine phosphorylation of MOR, (Kramer et al.; Zhang, et al.), which has been causally linked to the chronic morphine-induced activation of AC (AC super activation) as well as the conversion of MOR from a classical G-protein coupled receptor to a receptor tyrosine kinase-like receptor [46]. Additionally, Src has been reported to participate in delta opioid receptor activation of ERK [120]. Src activation by chronic opioids and consequent phosphorylation of multiple signaling molecules could concomitantly activate parallel tolerant mechanisms, all of which might be eliminated by Src inhibition. While this, hypothetically, could account for the ability of PP2 to interrupt opioid tolerance, it would not explain the ability of CSD to do the same, as was currently found. The most parsimonious explanation for our finding that PP2 and CSD have concordant effects on opioid anti-allodynic tolerance would be that PP2 and CSD acted at sequential steps in a common mechanism, PP2 inhibiting Src phosphorylation of Cav1, preventing the altered scaffolding that is critical to anti-allodynic morphine tolerance, CSD eliminating scaffolding by binding to the scaffolding site within Cav1.

Many cellular adaptations to chronic morphine have been described in cells maintained in culture and laboratory animal models. It remains unclear whether the lack of clinical utility of the most, if not all, of the previously intimated opioid tolerance mitigating therapies resulted from failure of the test or failure to test. Regardless, theoretically, there is a much greater likelihood for clinical success of developing opioid anti-tolerance pharmacotherapies that disrupt Cav1 scaffolding functionality in the presence of chronic opioids since doing so has the potential to concomitantly interrupt multiple analgesic/anti-allodynic tolerance mechanisms. The patent (WO 2021/158317 A1) processing has been delaying the submission for publication of this work, which provides an opportunity for other group to publish closely related work, yet with different focus and underlying mechanisms [86]. Although it tested the effect of Cav1 on morphine-induced hyperalgesia, it supports and emphasizes the clinical potential of our findings in preventing as well as reversing opioid tolerance in treating severe pain.

Disclosure Statement
The authors report there are no competing interests to declare.

Funding Details
This work was supported by the NIDA under Grant R01DA043774.

References

Citation: Liu N-J, Li H (2022) Disrupting Spinal Caveolin-1 Scaffolding Prevents as well as Reverses Tolerance to Opioid Antiallodynia in Treating Neuropathic Pain in Rats. J Reprod Med Gynecol Obstet 7: 0103.


Citation: Liu N-J, Li H (2022) Disrupting Spinal Caveolin-1 Scaffolding Prevents as well as Reverses Tolerance to Opioid Antiallodynia in Treating Neuropathic Pain in Rats. J Reprod Med Gynecol Obstet 7: 0103.


